Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8878719 | 0.83 | KDM4E (0.40) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL820846 | 0.82 | ACHE (0.42) | KDM4ECYP19A1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL820213 | 0.82 | ACHE (0.42) | KDM4ECYP19A1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL10388746 | 0.80 | KDM4E (0.57) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL15294423 | 0.80 | KDM4E (0.64) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL10448555 | 0.80 | KDM4E (0.45) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL10450126 | 0.80 | KDM4E (0.45) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL9348192 | 0.78 | KDM4E (0.52) | KDM4ECYP19A1SIGMAR1DRD2HTR2A | |
| SCHEMBL8877425 | 0.76 | HTR2C (0.41) | KDM4ESIGMAR1DRD2HTR2AHTR2C | |
| SCHEMBL9345561 | 0.75 | KDM4E (0.49) | KDM4ECYP19A1SIGMAR1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258477-B1 | CATALYST AND MICHAEL ADDITION REACTION PROCESS | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8222177-B2 | Catalyst and reaction process | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258477-A1 | CATALYST AND REACTION PROCESS | Japan Science and Technology Agency (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | KDM4E 2954/4885CYP19A1 365/4885SIGMAR1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.